The molecular imprinting technique can be traced as far back as the 1930s, but past attempts to use the technology for medical purposes have failed because of problems related to the purification process: When the polymer is down-sized, the result is a collection of MIPs particles with an uneven distribution of binding sites. Only a few of them have a high binding affinity, while the majority of the particles have no or very low binding affinity. Thus, without further purification most of the MIPs produced cannot be used for treatment as they lack the capability to bind the relevant template molecules.
Based on proprietary technology covered by various patent families comprising concept, production, and usage, MipSalus has made significant improvements to the general MIPs technology. These improvements expand the potential of the technology significantly and enable its use in various medical applications. Central to MipSalus’ technology is a new method used to sort MIPs particles according to their ability to bind the template molecule.
Using chromatography – a well-established industry technique used to separate components in a mixture – we are able to sort out and select the MIPs particles with high binding specificity and capacity. This is crucial in order to produce a MIPs-based drug with high specificity, reduce dosing level and side effects, and obtain the product homogeneity needed to meet regulatory authorities’ requirements.